RECURSION PHARMACEUTICALS, INC. Balance Sheet
RXRX / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 7 fiscal years. All figures from audited SEC 10-K filings.
RECURSION PHARMACEUTICALS, INC. had $1.5B in total assets and $1.1B in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $743.3M | $594.4M | $391.6M | $549.9M | $285.1M | $262.1M | - |
| Accounts Receivable | - | - | - | - | $34.0K | $156.0K | - |
| Current Assets | $812.8M | $714.3M | $438.1M | $569.8M | $534.7M | $266.4M | - |
| PP&E (Net) | $103.9M | $141.1M | $86.5M | $88.2M | $64.7M | $26.0M | - |
| Goodwill | $162.2M | $148.9M | $52.1M | $801.0K | $801.0K | $801.0K | - |
| Total Assets | $1.5B | $1.4B | $653.7M | $701.3M | $610.3M | $298.6M | - |
| Current Liabilities | $147.7M | $187.5M | $93.2M | $100.3M | $46.7M | $23.1M | - |
| Total Debt | - | - | - | - | $723.0K | - | - |
| Shareholders' Equity | $1.1B | $1.0B | $463.4M | -$206.3M | $542.9M | -$206.3M | -$124.3M |